Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Kidney Disease, Chronic: early-phase trial registry

4 of 8 indexed Kidney Disease, Chronic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Kidney Disease, Chronic: 8 US clinical trials tracked, 4 recruiting.

Kidney Disease, Chronic is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Rutgers, The State University of New Jersey, running 2 of these trials.

Enrollment posture brief

Registry condition kidney-disease-chronic

OPEN 4 | RECR 50% | LATE 1 | EARLY 3 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Kidney Disease, Chronic (thi…50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Kidney Disease, Chronic

Kidney Disease, Chronic lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Kidney Disease, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Kidney Disease, Chronic is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Kidney Disease, Chronic research.

    Rutgers, The State University of New Jersey accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Kidney Disease, Chronic trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. Kidney Disease, Chronic research is mostly interventional.

    6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Kidney Disease, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Empagliflozin Drug
2 trials
Epidiolex steady-state and tacrolimus single dose Drug
1 trials
Epidiolex single dose Drug
1 trials
Tacrolimus single dose Drug
1 trials
Medically Tailored Groceries Behavioral
1 trials
Lifestyle Medicine Program Behavioral
1 trials
Plant-based diet Behavioral
1 trials
Placebo matching BI 690517 Drug
1 trials

US sites by state

Facility locations filed on Kidney Disease, Chronic trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Ohio 2 trials
New Jersey 2 trials
North Carolina 2 trials
Missouri 2 trials
Michigan 2 trials
Maryland 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Kidney Disease, Chronic page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Disease, Chronic condition card totals 8 registered trials; most-linked intervention Empagliflozin; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.